. 2018 Oct 10;25(13):3919–3927. doi: 10.1245/s10434-018-6829-3

Table 5.

Staging and follow-up of the study population (mean follow-up: 60 ± 31 months)

Stage	T	N	M	Number of patients
Stage	T	N	M	Cured^a	Persisting disease^b	Recurrent disease^c	Total
I	1a	0	0	14			14
I	1b	0	0	7			7
II	2	0	0	4		1	5
II	3	0	0	3			3
III	1a	1a	0	2			2
	1b			1			1
	2			1			1
	3
IVA	4a	0/1a
	1a	1b	0	1			1
	1b			1	6		7
	2				1		1
	3				5 (died: 2^d)		5
IVB	4b	Any N	1
IVC	Any T	Any N	1		3 (died: 2^d)
			n	34 (68%)	15 (30%; died: 4.8%^d)	1	50

TNM, see Edge and Compton10 and Wells et al.12

bCt Basal calcitonin level

^aCured: At the time of follow-up, normal/undetectable bCt levels

^bPersisting disease: bCt levels never decreased to normal/undetectable values

^cRecurrent disease: Normalization of bCt levels for at least 1 year, than a recurrent increase

^dn patients died of MTC